Gastroretentive Floating Capsules of Risedronate Sodium: Development, Optimization, in vitro and in vivo Evaluation in Healthy Human Volunteers
DOI:
https://doi.org/10.37285/ijpsn.2015.8.2.6Abstract
Background and the purpose of the study: Risedronate sodium inhibits osteoclast bone resorption and modulates bone metabolism. Risedronate has a high affinity for hydroxyapatite crystals in bone and is a potent antiresorptive agent. In the present investigation efforts were made to improve the bioavailability of risedronate sodium by increasing the residence time of the drug through sustained-release matrix capsule formulation via gastroretentive mechanism. Capsules were prepared by wet granulation technique. The influence of gel forming agents, amount of risedronate and total weight of capsules on physical properties, in vitro buoyancy, drug release, FTIR, DSC, X-ray studies were investigated. The release mechanisms were explored and explained by applying zero order, first order, Higuchi and Korsmeyer equations. The selected formulations were subjected to stability study at 40 °C/75% RH, 25 °C/60% RH for the period of three months. For all formulations, kinetics of drug release from capsules followed Higuchi’s square root of time kinetic treatment heralding diffusion as predominant mechanism of drug release. Formulation containing 25 mg HPMC K4M and 75 mg HPMC K100 LV (F-8) showed zero order release profile. There was no significant change in the selected formulation, when subjected to accelerated stability conditions over a period of three months. X-ray imaging in six healthy human volunteers revealed a mean gastric retention period of 5.60 ± 0.77 hrs for the selected formulation. Stable, sustained release effervescent floating capsules of risedronate sodium could be prepared by wet granulation technique.
Downloads
Metrics
Keywords:
Differential Scanning Calorimeter, Risedronate sodium, Gelucire, Polyox, in vivo gastric retention
Downloads
Published
How to Cite
Issue
Section
References
Chandrasekhar BB (2012). Floating Systems for Oral Controlled Release Drug Delivery. Int J App Pharm. 4(2):1-13.
Harshal PG, Manohar VP, Bharat WT, Vinod MT, Patil VR (2012). Formulation and in-vitro Evaluation of Trifluoperazine Hydrochloride Bilayer Floating Tablet. Int J Pharm Bio Sci. 2(1): 166-172.
Higuchi T (1961). Rate of Release of Medicaments from Ointment Bases Containing Drugs in Suspensions. J Pharm Sci. 50(10): 874-875.
Malay RP, Amit AP, Laxman MP and Natvarlal MP (2012). Intragastric Floating Drug Delivery System of Metformin Hydrochloride as Sustained Release Component and Glimepiride as Immediate Release Component: Formulation and Evaluation. Int J Pharm Sci . 4(3): 299-303.
Mohan G, Rames h B and Kishan V (2011). Development of Sustained Release Floating Drug Delivery System for Norfloxacin: In vitro and In vivo Evaluation. PDA J Pharm Sci Tech. 65(3): 198-206.
Santhana laxmi G, Elango K, Ramesh Kumar K, Farheen F (2012). Formulation and Evaluation of Bilayer Floating Tablets of Trimetazidine Hcl and Metoprolol Succinate. Ind J Pharm Edu Res. 46 (3): 259-264.
Sarfaraz Md, Keerthi CRP, Udupi RH and Doddayya H (2012). Formulation and In-Vitro Evaluation of Bilayer Floating Tablets of Tramadol Hcl. Int J Drug Dev Res. 4(3): 335-347.
Senthil A, Suresh Kumar P, Raju CH and Mohideen S (2010). Formulation and Evaluation of Gastric Oral Floating Tablet of Glipizide. Int J Bio Pharm Res . 1(2):108-113.
Singh BN and Kim KH (2000). Floating Drug Delivery Systems an Approach to Oral Controlled Drug Delivery via Gastric Retention. J Control Rel . 63(3): 235-59.
Siepmann J, Peppas NA (2001). Modelling of Drug Release from Delivery Systems based on Hydroxypropyl Methylcellulose. Adv Drug Del Res. 48(2001): 139-157.
Sivabalan M, Vani T, Phaneendhar R, Anup J and Nigila G(2011). Formulation and Evaluation of Gastroretentive Glipizide Floating Tablets. Int J Compreh Pharm . 2(1): 1-4.
Streubel A, Siepmann J and Bodmeier R(2006). Gastroretentive Drug Delivery System. Expert Opin Drug Deliv. 3(2): 217- 233.
Tadros MI(2010). Controlled-release Effervescent Floating Matrix Tablets of Ciprofloxacin Hydrochloride: Development, Optimization and In Vitro–In Vivo Evaluation in Healthy Human Volunteers. Eur J Pharm Biopharm. 74: 332-33.
